Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
JBIO
JBIO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
JBIO News
Jade Biosciences Reports $31.9 Million Net Loss for Q4 2025
4d ago
seekingalpha
Jade Biosciences Clinical Progress and Financial Update
5d ago
Newsfilter
HC Wainwright Initiates Buy on Jade Biosciences with $25 Price Target
Jan 07 2026
Benzinga
Jade Biosciences Outlines 2026 Strategic Priorities and Clinical Developments
Jan 05 2026
NASDAQ.COM
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
Jan 02 2026
Benzinga
JBIO Rises More Than 75% in Two Months Due to Pipeline Progress - Did You Invest?
Dec 17 2025
NASDAQ.COM
Jade Biosciences Secures $45 Million Financing from BB Biotech
Dec 15 2025
Globenewswire
Jade Biosciences Secures $45 Million Financing from BB Biotech
Dec 15 2025
Newsfilter
Clear Street Begins Coverage of Jade Biosciences with a Buy Rating and Sets Price Target at $25
Nov 25 2025
Benzinga
Reasons to Consider Jade Biosciences, Inc. (JBIO) as a New Investment Opportunity
Nov 18 2025
NASDAQ.COM
Significant Options Activity on Tuesday: WBD, C, JBIO
Nov 18 2025
NASDAQ.COM
Major Stocks on the Rise Monday: Jazz Pharmaceuticals, Sigma Lithium, Zymeworks, and More
Nov 17 2025
Benzinga
Significant Options Activity on Monday: JBIO, MU, GOOGL
Nov 10 2025
NASDAQ.COM
Jade Biosciences Unveils New Findings Highlighting Positive Preclinical Safety of JADE101 and APRIL-Mediated Biomarker Responses at the 2025 American Society of Nephrology Kidney Week
Nov 08 2025
Yahoo Finance
BTIG Begins Coverage of Jade Biosciences with a Buy Rating and Sets Price Target at $28
Oct 09 2025
Benzinga
Jade Biosciences Unveils JADE201, a Promising Long-Lasting Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Treating Autoimmune Disorders
Oct 07 2025
Newsfilter
Show More News
